

- Osteomyelitis (*Cont.*):
P. aeruginosa, 1045t, 1046
 pathogenesis of, 194e-2, 838-839, 844
 in prosthetic joints. *See* Prosthetic joint infections
 psoas abscess in, 852
 in returning war veterans, 152e-6t, 152e-9
S. aureus, 957, 957f
 skull-base, 229
 sternal, 844-845, 844f
 treatment of, 840t, 841t, 963, 1102, 2429
 tuberculous, 836, 839, 844
 vertebral, 957, 957f, 1046
 clinical features of, 117, 839
 complications of, 841
 diagnosis of, 117, 839-840, 842f
 epidemiology of, 839
 microbiology of, 839
 pathogenesis of, 839
 treatment of, 840-841, 840t, 841t
- Osteonecrosis
 drug-induced, 2218t
 in HIV infection, 1261
 in IBD, 1958
 of jaw, 242, 623, 2481, 2501
 oral, 46e-4f
- Osteopathic medicine, 14e-1t, 14e-2
- Osteopenia, 2218t
- Osteopetrosis, 426e-4
- Osteopoikilosis, 426e-5
- Osteopontin, 89e-2
- Osteoporosis, **2488**
 approach to the patient, 2494-2495, 2495t
 back pain in, 117
 biochemical markers in, 2494-2495, 2494t
 bone biopsy in, 2494
 bone mass measurement in, 2493, 2493f, 2493t
 definition of, 2488
 diet and, 95e-5
 differential diagnosis of, 2494
 epidemiology of, 2488
 fractures in
 epidemiology of, 2488-2489, 2488f
 management of, 2495
 prevention of, 2499-2502, 2500f, 2502f
 risk factors for, 2489, 2490t
 glucocorticoid-induced, 2503-2504
 heparin-induced, 752
 in HIV infection, 1261
 in liver disease, 2067
 pathophysiology of, 2489-2490, 2491f
 prednisone and, 2145
 prevalence of, 2254t
 prevention of, 84, 2383, 2384t
 in rheumatoid arthritis, 2138
 risk factors for, 2489, 2490t
 assessment of, 2495-2496, 2496f
 chronic disease, 2492
 cigarette smoking, 2493
 estrogen status, 2491-2492, 2492f
 low calcium intake, 2491
 medications, 2492-2493
 physical inactivity, 2492
 vitamin D deficiency in, 2491
 screening for, 28, 29t, 84, 2254t
 treatment of, 117, **2495**
 anabolic agents, 2503
 bisphosphonates, 2499-2501, 2500f
 calcitonin, 2501
 calcium supplementation, 2496-2497, 2496t, 2497t
 denosumab, 2501, 2502f
 estrogens, 2497-2498, 2498f
 exercise, 2497
 fluoride, 2503
 GH, 2503
 monitoring of, 2503
 nonpharmacologic, 2503
 nutritional recommendations, 2496
 progestins, 2498
 PTH, 2502-2503, 2503f
 risk factor reduction, 2495-2496, 2496f
 SERMs, 2498-2499
 strontium ranelate, 2503
 vitamin D, 2497
 vertebral fracture in, 117
 in women, 6e-4
- Osteoprotegerin (OPG)
 in bone metastasis, 102e-10-11
 in bone remodeling, 2490, 2492f
 in osteopetrosis, 426e-4
 in primary myelofibrosis, 675
- Osteosarcoma, 101e-2t, **119e-3**, 236
- Osteosclerosis, 118, 426e-5, 675. *See also* Paget's disease of bone
- Ostium primum, 51e-4, 1520
- Ostium secundum, 51e-4, 1520
- Otitis externa, 228-229, 1045t, 1046-1047, 1348
- Otitis media, **229**
 acute, 229-230, 229t, 952, 953
 anaerobic bacterial, 1097
 brain abscess associated with, 901
C. auris, 981
 chronic, 230, 1097
 clinical features of, 230, 952
H. influenzae, 229-230, 1011
 hearing loss in, 217
 in influenza, 1212
M. catarrhalis, 229-230, 1013
 in nasopharyngeal cancer, 503
 recurrent, 230
 serous, 230
 treatment of, 229t, 230, 953
- Otoacoustic emissions, 219
- Otosclerosis, 219
- Otology, 217
- OTUs (operational taxonomic units), 86e-2
- Outcome (quality theory), 12e-2
- Outcome evaluation, 3
- Outer-membrane vesicles (OMVs), 1002, 1002f
- Outpatient care, 5
- Ova and parasite examination, 267
- Ovalocytosis, malaria resistance and, 1371
- Ovarian cancer, **592**
 breast cancer and, 592
 carcinoma of unknown primary and, 120e-3
 clinical features of, 592-593
 deaths from, 467t, 469f, 470t
 epidemiology of, 592
 epithelial, 592-593
 genetic considerations in, 101e-2t, 101e-6t, 523, 592
 germ cell tumors, 594-595
 incidence of, 467t, 592, 593
 infections in, 484t
 metastatic, 408
 oral contraceptives and, 2391t
 paraneoplastic syndromes in
 endocrinologic, 609t
 hematologic, 612, 612t
 neurologic, 614t, 615f, 617
 pathogenesis of, 592
 pathology of, 592
 postmenopausal hormone therapy and, 2384t, 2386
 during pregnancy, 124e-1t
 prognosis of, 593t, 594
 protective factors for, 592
 recurrent, 593-594
 risk factors for, 592
 screening for, 482, 593
 sex cord tumors, 594
 staging of, 593, 593t
 surgical prevention of, 479
 treatment of, 593-594
 tumor markers in, 473t, 593
- Ovarian follicles, 2376, 2376f
- Ovarian neuroendocrine tumors (carcinoids), 564
- Ovarian reserve, 2388
- Ovary
 development of, 2375-2376, 2375f, 2376f
 disorders of
 cancer. *See* Ovarian cancer
 cyst, 106, 404
 drug-related, 2132
 dysfunction/failure, 336-337, 437, 2388, 2389
 sex cord tumors, 594
 teratoma. *See* Teratoma, ovarian
 function of, **2376**
 assessment of, 2379
 hypothalamic secretion in, 2376-2377, 2377f
 ovarian peptides in, 2378
 ovarian steroids in, 2377-2378, 2377f. *See also* Estrogen(s); Progesterone
 pituitary secretion in, 2376-2377, 2377f
 metastatic disease to, 593
- Overactive bladder, 7e-4, 60e-2
- Overdiagnosis, 479, 509
- Overdosage. *See* Poisoning/drug overdose
- Overflow diarrhea, 265
- Overflow incontinence, 80-81
- Overlapping sphincteroplasty, 1976
- Overweight, 98e-1t, 415e-1, 2393t. *See also* Obesity
- Ovotesticular disorders of sexual development, 2351t, 2353
- Oxacillin
 adverse effects of, 306, 2023
 for burn-wound infections, 166e-3
 for cellulitis, 832t
 indications for, 937, 940t
 for infective endocarditis, 823
 for nongonococcal bacterial arthritis, 835
 for osteomyelitis, 840t, 841t
 resistance to, 933, 940t
 for staphylococcal infections, 961, 962t
- Oxalate, 318, 319, 1867
- Oxaliplatin
 action of, 103e-12
 adverse effects of, 103e-9t, 103e-12, 543, 1793
 for colorectal cancer, 543
 for pancreatic cancer, 557
- Oxalosis, 62e-10f, 2237, 2237f
- Oxamniquinone, 246e-5t, 246e-11
- Oxandrolone, 2371
- Oxazepam, 473e-10t, 1606, 2711t
- Oxazolidinones, 931t, 932, 932f. *See also* Linezolid; Tedizolid
- Oxcarbazepine
 adverse effects of, 2554t, 2718t
 for anxiety disorders, 2711
 for bipolar disorder, 2718, 2718t
 drug interactions of, 2554t
 for epilepsy, 2552, 2554t
 overdose/poisoning with, 473e-10t
 for pain, 61, 91t
 pharmacology of, 2554t, 2718
 for trigeminal neuralgia, 2646
- Oxicam, 383
- Oxidative phosphorylation, 462e-15
- Oxidative stress
 aging and, 75, 94e-3, 94e-7, 2450
 in asthma, 1674
 metabolic syndrome and, 2450
- P450 Oxidoreductase deficiency, 2328t
- Oxime therapy, 262e-5t, 262e-6, 262e-6f
- 5-Oxoproline, 320
- 3-Oxothiolase deficiency, 434e-3t
- Oxybutynin, 192, 2660, 2672
- Oxycodone
 abuse of. *See* Opioid use disorders
 for dyspnea, 62t
 for pain, 91t
- Oxygen
 arterial concentration of, 1748t, 2762t
 plasma concentration of, 1748t
 toxicity of, 477e-2
 transport in blood, 631
 venous concentration of, 1748t, 2762t
- Oxygen-carrying capacity of hemoglobin, 632, 1748t
- Oxygen delivery, 1733, 1748t
- Oxygen delivery index, 1748t
- Oxygen extraction ratio, 1748t
- Oxygen-hemoglobin dissociation curve, 247, 393, 632, 632f